S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
Log in
NASDAQ:AXLA

Axcella Health Stock Forecast, Price & News

$5.51
-0.17 (-2.99 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.50
Now: $5.51
$5.73
50-Day Range
$5.21
MA: $5.98
$6.72
52-Week Range
$2.25
Now: $5.51
$7.73
Volume111,624 shs
Average Volume79,299 shs
Market Capitalization$206.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Axcella Health Inc., a clinical-stage biotechnology company, researches and develops endogenous metabolic modulators (EMMs) for the treatment of complex diseases and improving health in the United States. It offers AXA1665 for use in treating overt hepatic encephalopathy; AXA1125 and AXA1957 to treat non-alcoholic steatohepatitis; AXA2678 for use in treating muscle atrophy; and AXA4010 to target multiple biological pathways to support normal structures and functions of the blood. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Axcella Health logo

Headlines

Axcella Announces Upcoming Presentations at NASH-TAG 2021
February 25, 2021 |  finance.yahoo.com
Where Do Hedge Funds Stand On Axcella Health Inc. (AXLA)?
November 27, 2020 |  finance.yahoo.com
Axcella Health EPS beats by $0.04
November 12, 2020 |  seekingalpha.com
Axcella Health, Inc. to Host Earnings Call
November 12, 2020 |  finance.yahoo.com
Why Axcella (AXLA) Might Surprise This Earnings Season
November 11, 2020 |  finance.yahoo.com
Axcella Health Inc
October 30, 2020 |  bloomberg.com
Axcella Health Inc. (AXLA)
October 16, 2020 |  finance.yahoo.com
Company Profile for Axcella Health Inc.
September 24, 2020 |  businesswire.com
Axcella to Present at Upcoming Investor Conferences
September 8, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXLA
CUSIPN/A
CIKN/A
Phone857-320-2200
Employees66
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.61 per share

Profitability

Net Income$-59,040,000.00

Miscellaneous

Market Cap$206.85 million
Next Earnings Date3/22/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.58 out of 5 stars

Medical Sector

372nd out of 1,969 stocks

Biological Products, Except Diagnostic Industry

50th out of 177 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$5.51
-0.17 (-2.99 %)
(As of 03/4/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AXLA News and Ratings via Email

Sign-up to receive the latest news and ratings for AXLA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Axcella Health (NASDAQ:AXLA) Frequently Asked Questions

Is Axcella Health a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Axcella Health stock.
View analyst ratings for Axcella Health
or view top-rated stocks.

What stocks does MarketBeat like better than Axcella Health?

Wall Street analysts have given Axcella Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Axcella Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Axcella Health's next earnings date?

Axcella Health is scheduled to release its next quarterly earnings announcement on Monday, March 22nd 2021.
View our earnings forecast for Axcella Health
.

How were Axcella Health's earnings last quarter?

Axcella Health Inc. (NASDAQ:AXLA) posted its earnings results on Tuesday, November, 17th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.07.
View Axcella Health's earnings history
.

How has Axcella Health's stock been impacted by Coronavirus?

Axcella Health's stock was trading at $3.32 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AXLA shares have increased by 66.0% and is now trading at $5.51.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AXLA?

9 equities research analysts have issued twelve-month price objectives for Axcella Health's stock. Their forecasts range from $9.00 to $28.00. On average, they expect Axcella Health's stock price to reach $17.13 in the next twelve months. This suggests a possible upside of 210.8% from the stock's current price.
View analysts' price targets for Axcella Health
or view top-rated stocks among Wall Street analysts.

Who are Axcella Health's key executives?

Axcella Health's management team includes the following people:
  • Mr. William R. Hinshaw Jr., Pres, CEO & Director (Age 52, Pay $785.48k)
  • Dr. Manu V. Chakravarthy M.D., Ph.D., Exec. VP of Clinical Devel. & Chief Medical Officer (Age 47, Pay $529.21k)
  • Mr. Laurent Chardonnet, Sr. VP & CFO (Age 56)
  • Dr. Paul Fehlner J.D., Ph.D., Sr. VP, Chief Legal Officer & Corp. Sec. (Age 57)
  • Dr. Larry Bell, Global Head of Regulatory Affairs & Pharmacovigilance and Sr. VP

What is Bill Hinshaw's approval rating as Axcella Health's CEO?

3 employees have rated Axcella Health CEO Bill Hinshaw on Glassdoor.com. Bill Hinshaw has an approval rating of 100% among Axcella Health's employees. This puts Bill Hinshaw in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Axcella Health's key competitors?

What other stocks do shareholders of Axcella Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Evofem Biosciences (EVFM), ADMA Biologics (ADMA), Coty (COTY), Energy Transfer (ET), Myovant Sciences (MYOV), NVIDIA (NVDA), Pfizer (PFE) and Moderna (MRNA).

When did Axcella Health IPO?

(AXLA) raised $76 million in an IPO on Thursday, May 9th 2019. The company issued 3,600,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink acted as the underwriters for the IPO.

What is Axcella Health's stock symbol?

Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."

Who are Axcella Health's major shareholders?

Axcella Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.72%), Northern Trust Corp (0.51%), Zacks Investment Management (0.35%), Bank of New York Mellon Corp (0.23%), Dimensional Fund Advisors LP (0.22%) and Renaissance Technologies LLC (0.16%). Company insiders that own Axcella Health stock include Catherine A Sohn, D Clay Bretches, David R Epstein, Laurent Chardonnet, Manu Chakravarthy and Ventures Fund Iv LP Flagship.
View institutional ownership trends for Axcella Health
.

Which institutional investors are selling Axcella Health stock?

AXLA stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Zacks Investment Management, JPMorgan Chase & Co., and Barclays PLC.
View insider buying and selling activity for Axcella Health
or view top insider-selling stocks.

Which institutional investors are buying Axcella Health stock?

AXLA stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, BlackRock Inc., GSA Capital Partners LLP, Dimensional Fund Advisors LP, Northern Trust Corp, Virtu Financial LLC, Rhumbline Advisers, and Wells Fargo & Company MN. Company insiders that have bought Axcella Health stock in the last two years include Catherine A Sohn, D Clay Bretches, David R Epstein, Laurent Chardonnet, and Ventures Fund Iv LP Flagship.
View insider buying and selling activity for Axcella Health
or or view top insider-buying stocks.

How do I buy shares of Axcella Health?

Shares of AXLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axcella Health's stock price today?

One share of AXLA stock can currently be purchased for approximately $5.51.

How much money does Axcella Health make?

Axcella Health has a market capitalization of $206.85 million. The company earns $-59,040,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis.

How many employees does Axcella Health have?

Axcella Health employs 66 workers across the globe.

What is Axcella Health's official website?

The official website for Axcella Health is www.axcellahealth.com.

Where are Axcella Health's headquarters?

Axcella Health is headquartered at 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139.

How can I contact Axcella Health?

Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-320-2200 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.